Factors associated with knowledge, confidence, self-efficacy, and satisfaction in African American men's decisions about prostate cancer screening

Background: African American men (AAM) have persistently had the highest incidence and mortality rates for prostate cancer (PrCa) in the United States. Considering that current guidelines recommend the practice of shared decision-making to determine whether or not to undergo a Prostate-Specific Antigen (PSA) test for the early detection of PrCa, this study focuses on the identification of key factors influencing AAM decisions regarding having or not having PSA screenings. Methods: Cross-sectional study of 152 AAM who completed study surveys. Statistical analysis included frequencies, means, and distributions and methods to test for differences in knowledge confidence, satisfaction and, self-efficacy when making decisions. Results: 94% of participants would get a PSA test if offered, only 57% knew that the PSA test is a blood test. Participants who reported having had a PSA test before the baseline had significantly higher mean scores than their counterparts in the knowledge about the definition of the PSA and biopsy exams (p = 0.04), and in the confidence (p = 0.005) and efficacy (p = 0.002) scales when making PSA screening decisions. Older participants were more likely to have had a PSA test (p < 0.0001) and to intend to screen (p = 0.0441). Conclusions: Significant differences in the satisfaction scale by clinical site (p < 0.001) may underscore the influence of clinicians’ practices in participants’ satisfaction with their decisions. Results suggest that patients’ experience of care has the potential to positively influence PSA screening. It is our call that type of health insurance, knowledge about PrCa and PSA, and having had a PSA test in the past, as well as the patient’s characteristics (age, race and family history of PrCa) be considered when discussing with patients the harms/benefits of PSA screening and their preferences to have or not have the PSA test.

Prostate cancer; Prostate-specific antigen (PSA); PSA screening; African American men; Baseline assessment; Confidence, satisfaction and efficacy

[1] U.S. Preventive Services Task Force (USPSTF). Procedure manual appendix I. Congressional mandate establishing the U.S. preventive services task force. 2019. Available at: https://uspreventiveservicestaskforce.org/uspstf/about-uspstf/methods-and-processes/procedure-manual/procedure-manual-appendix-i (Accessed: 14 June 2024).

[2] US Preventive Services Task Force; Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB, Davidson KW, et al. Screening for prostate cancer: US preventive services task force recommendation statement. JAMA. 2018; 319: 1901–1913.

[3] Ferraro S, Biganzoli D, Rossi RS, Palmisano F, Bussetti M, Verzotti E, et al. Individual risk prediction of high grade prostate cancer based on the combination between total prostate-specific antigen (PSA) and free to total PSA ratio. Clinical Chemistry and Laboratory Medicine. 2023; 61: 1327–1334.

[4] Ferraro S, Bussetti M, Panteghini M. Serum prostate-specific antigen testing for early detection of prostate cancer: managing the gap between clinical and laboratory practice. Clinical Chemistry. 2021; 67: 602–609.

[5] National Quality Forum (NQF). National quality partners playbook. Shared decision making in healthcare. 2018. Available at: https://www.qualityforum.org/Publications/2018/03/Shared_Decision_Making_in_Healthcare.aspx (Accessed: 14 June 2024).

[6] American Cancer Society (ACS). Cancer facts & figures 2023. 2023. Available at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2023/2023-cancer-facts-and-figures.pdf (Accessed: 14 June 2024).

[7] American Cancer Society (ACS). Cancer facts & figures 2022. 2022. Available at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2022/2022-cancer-facts-and-figures.pdf (Accessed: 14 June 2024).

[8] Garraway IP, Carlsson SV, Nyame YA, Vassy JL, Chilov M, Fleming M, et al. Prostate cancer foundation screening guidelines for black men in the United States. NEJM Evidence. 2024; 3: EVIDoa2300289.

[9] Lewis-Thames MW, Khan S, Hicks V, Drake BF. Predictors of annual prostate-specific antigen (PSA) screening among black men: results from an urban community-based prostate cancer screening program. Journal of Men’s Health. 2021; 17: 78–83.

[10] Qin W, Hamler TC, Miller DB. Self-efficacy and importance of participation reasons as predictors for prostate cancer screening intention in African American men. Ethnicity & Health. 2022; 27: 316–328.

[11] Coughlin SS, Ayyala DN, Luque JS, Moore JX. Predictors of prostate cancer screening among African American men treated at an Academic Medical Center in the Southern United States. Current Cancer Reports. 2021; 15: 81–94.

[12] Woods VD, Montgomery SB, Herring RP, Gardner RW, Stokols D. Social ecological predictors of prostate-specific antigen blood test and digital rectal examination in black American men. Journal of the National Medical Association. 2006; 98: 492–504.

[13] The Federal Reserve. Survey of household economics and decision-making (SHED). Economic Well-Being of U.S. Households in 2022. 2024. Available at: https://www.federalreserve.gov/consumerscommunities/shed.htm (Accessed: 14 June 2024).

[14] Haun J, Noland-Dodd V, Varnes J, Graham-Pole J, Rienzo B, Donaldson P. Testing the BRIEF health literacy screening tool. Federal Practitioner. 2009; 26: 24–31.

[15] Radosevich DM, Partin MR, Nugent S, Nelson D, Flood AB, Holtzman J, et al. Measuring patient knowledge of the risks and benefits of prostate cancer screening. Patient Education and Counseling. 2004; 54: 143–152.

[16] O’Connor AM. Patient decision aides, user manuals. Decisional conflict scale. 1993. Available at: https://decisionaid.ohri.ca/docs/develop/User_Manuals/UM_decisional_conflict.pdf (Accessed: 18 August 2023).

[17] Holmes-Rovner M, Kroll J, Schmitt N, Rovner DR, Breer ML, Rothert ML, et al. Patient satisfaction with health care decisions: the satisfaction with decision scale. Medical Decision Making. 1996; 16: 58–64.

[18] Smith MY, Winkel G, Egert J, Diaz-Wionczek M, DuHamel KN. Patient-physician communication in the context of persistent pain: validation of a modified version of the patients’ Perceived Involvement in Care Scale. Journal of Pain and Symptom Management. 2006; 32: 71–81.

[19] Kutner M, Nachtsheim C, Neter J. Multiple Regression II. In Kutner M, Nachtsheim C, Neter J (eds.) Applied linear regression models (pp. 256–293). 4th edn. McGraw-Hill/Irvin: Boston, NY. 2004.

[20] Brook MN, Ní Raghallaigh H, Govindasami K, Dadaev T, Rageevakumar R, Keating D, et al. Family history of prostate cancer and survival outcomes in the UK genetic prostate cancer study. European Urology. 2023; 83: 257–266.

[21] Rositch AF, Atnafou R, Krakow M, D’Souza G. A community-based qualitative assessment of knowledge, barriers, and promoters of communicating about family cancer history among African-Americans. Health Communication. 2019; 34: 1192–1201.

[22] Mastalski K, Coups EJ, Ruth K, Raysor S, Giri VN. Substantial family history of prostate cancer in black men recruited for prostate cancer screening: results from the Prostate Cancer Risk Assessment Program. Cancer. 2008; 113: 2559–2564.

[23] Drake BF, Lathan CS, Okechukwu CA, Bennett GG. Racial differences in prostate cancer screening by family history.  Annals of Epidemiology. 2008; 18: 579–583.

[24] Krakow M, Rising CJ, Trivedi N, Yoon DC, Vanderpool RC. Prevalence and correlates of family cancer history knowledge and communication among US adults.  Preventing Chronic Disease. 2020; 17: E146.

[25] U.S. Centers for Medicare and Medicaid Services. Prostate cancer screenings. 2024. Available at: https://www.medicare.gov/coverage/prostate-cancer-screenings (Accessed: 14 June 2024).

[26] American Cancer Society (ACS). Insurance coverage of prostate cancer screening. 2023. Available at: https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/insurance-coverage.html (Accessed: 14 June 2024).

[27] Echeverri M, Yanes E, Anderson D, Nápoles AM. Prostate Specific Antigen (PSA) testing practices in an academic healthcare organization. Journal of Men’s Health.  2022; 18: 074.

[28] Guber R, Kocher MG, Winter J. Does having insurance change individuals’ self-confidence? Journal of Risk and Insurance. 2021; 88: 429–442.

[29] University Medical Center New Orleans (UMC). UMC 2021 Fact Sheet. 2021. Available at: https://www.lcmchealth.org/documents/content/UMC-2021-Fact-Sheet_19-1966-final.pdf (Accessed: 14 June 2024).

[30] Rezaee ME, Ward CE, Sverrisson EF, Dagrosa LM. Brief report: impact of healthcare quality on prostate specific antigen screening for the early detection of prostate cancer. Preventive Medicine Reports. 2019; 14: 100838.

[31] Hayat Roshanai A, Nordin K, Berglund G. Factors influencing primary care physicians’ decision to order prostate-specific antigen (PSA) test for men without prostate cancer.  Acta Oncologica. 2013; 52: 1602–1608.

[32] Alford NA, Wongpaiboon M, Luque JS, Harris CM, Tawk RH. Associations of content and context of communication with prostate-specific antigen testing.  International Journal of Environmental Research and Public Health. 2023; 20: 5721.

[33] Tulane Medical Center. Tulane doctors—urology: services & specialists. 2024. Available at: https://medicine.tulane.edu/tulane-doctors/urology/services-specialties (Accessed: 14 June 2024).

[34] Tulane Medical Center. Tulane Doctors—Tulane Medical Center. Man up with Rickey Jackson: free prostate cancer screening event. 2024. Available at: https://www.lcmchealth.org/tulane-medical-center/blog/2022/september/man-up-with-rickey-jackson-free-prostate-cancer-/ (Accessed: 14 June 2024).

[35] Althubaiti A. Information bias in health research: definition, pitfalls, and adjustment methods. Journal of Multidisciplinary Healthcare. 2016; 9: 211–217.